NDA 208587 · Emmaus Medcl
Endari
L-Glutamine · Oral · Amino Acid
OrphanLast checked: Nov 19, 2026Latest source record: Jun 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jul 7, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
150
32 Phase 3, 9 recruiting
FAERS reports
4,606
2,873 serious, 128 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 20, 2025.
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. ENDARI is an amino acid indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. ( 1 )
Mechanism: The mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD + and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 7, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
- ENDARI · L-GLUTAMINE 5GM/PACKET · FOR SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "L-Glutamine" as an intervention, any sponsor and status, largest first.
- Glutamine Supplementation to Prevent Death or Infection in Extremely Premature InfantsPivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT00005775 · 1,433 participants · Start Jul 1999 · Primary completion Dec 2000
Drug: Glutamine; Placebo · For: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age and 2 more
Sites: Birmingham, Alabama; Palo Alto, California; San Diego, California · 15 sites in all
- Scandinavian Intensive Care Unit (ICU) Glutamine StudyPivotal-lookingTerminated
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT00922714 · 1,000 participants (planned) · Start Oct 2003 · Primary completion May 2007
Drug: Glutamine; saline (placebo) · For: ICU Patients
Sites: Stockholm, Sweden
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Calithera Biosciences, IncIndustry
NCT03428217 · 444 participants · Start Apr 24, 2018 · Primary completion Aug 31, 2020
Drug: CB-839; Cabozantinib and 1 more · For: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 133 sites in all
- Long-term Impact and Intervention for Diarrhea in BrazilPivotal-lookingStatus unknown
University of VirginiaAcademic, hospital or other
NCT00133406 · 321 participants (planned) · Start Jun 2006 · Primary completion Dec 2011
Drug: Glutamine; Vitamin A and 2 more · For: Diarrheal Disorder
Sites: Fortaleza, Brazil
- The CRISIS Prevention StudyPivotal-lookingTerminated
Michael DeanAcademic, hospital or other
NCT00395161 · 293 participants · Start Apr 2007 · Primary completion Nov 2009
Drug: Metoclopramide; Zinc and 1 more · For: Sepsis
Sites: Little Rock, Arkansas; Los Angeles, California; Washington D.C., District of Columbia · 7 sites in all
- Safety, Tolerability, and Efficacy of AXA1125 in NASH With FibrosisPivotal-lookingStatus unknown
Axcella Health, IncIndustry
NCT04880187 · 273 participants (planned) · Start May 7, 2021 · Primary completion Sep 2023
Drug: AXA1125; Placebo · For: Non Alcoholic Steatohepatitis (NASH)
Sites: Cullman, Alabama; Tucson, Arizona; Canoga Park, California · 75 sites in all
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)Pivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT04305769 · 260 participants (planned) · Start Jun 1, 2021 · Primary completion Dec 31, 2026
Drug: Alanyl-glutamine · For: Clostridioides Difficile Infection; Clostridium Difficile Infection; Clostridium Difficile Diarrhea and 1 more
Sites: Charlottesville, Virginia; Roanoke, Virginia
Lynk Biotechnologies Pte LtdIndustry
NCT03743896 · 240 participants · Start May 18, 2016 · Primary completion Mar 10, 2017
Drug: Transdermal Glucosamine Cream · For: Osteoarthritis, Knee
Sites: Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sickle cell anaemia with crisis1,751
- product dose omission issue723
- pain281
- product dose omission272
- nausea241
- headache214
- hospitalisation212
- diarrhoea201
- abdominal pain upper160
- constipation152
- fatigue150
- drug dose omission132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 18 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 10 |
| 2009 | 7 |
| 2010 | 18 |
| 2011 | 17 |
| 2012 | 32 |
| 2013 | 22 |
| 2014 | 28 |
| 2015 | 47 |
| 2016 | 88 |
| 2017 | 96 |
| 2018 | 781 |
| 2019 | 608 |
| 2020 | 439 |
| 2021 | 260 |
| 2022 | 352 |
| 2023 | 456 |
| 2024 | 707 |
| 2025 | 361 |
| 2026 | 232 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Endari (Glutamine)
2024 spending
$5.3M
Beneficiaries
490
1,638 claims
Per beneficiary
$10,868
$22.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,343,530 |
| 2021 | $6,651,056 |
| 2022 | $6,571,999 |
| 2023 | $8,272,577 |
| 2024 | $5,325,108 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Update on the treatment of chemotherapy and radiotherapy-induced buccal mucositis: a systematic review.
Wen S, Brito L, Santander J, et al. · Acta Odontol Latinoam 2023 · Systematic Review
- Multi-cohort analysis of depression-associated gut bacteria sheds insight on bacterial biomarkers across populations.
Liang S, Sin ZY, Yu J, et al. · Cell Mol Life Sci 2022 · Meta-Analysis
- L-arginine vs. L-glutamine oral suspensions for radiation-induced oral mucositis: a triple-blind randomized trial.
Hassanein FEA, Mikhail C, Elkot S, et al. · J Cancer Res Clin Oncol 2025 · Randomized Controlled Trial
- Supplemental Protein and a Multinutrient Beverage Speed Wound Healing after Acute Sleep Restriction in Healthy Adults.
Smith TJ, Wilson M, Whitney C, et al. · J Nutr 2022 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Impact of preoperative beta-hydroxy-beta-methylbutyrate, arginine, and glutamine supplementation on inflammation in patients with cardiac surgery: A secondary analysis of a randomized controlled trial.
Ogawa M, Satomi-Kobayashi S, Yoshida N, et al. · J Cardiol 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Emmaus Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.